RESvEraTrol in Parkinson's Disease (RESET)

This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.

NCT Number	NCT07592767
Lead Sponsor	Georgetown University Collaborators: Jupiter Neuroscience Inc., Medstar Health Research Institute
Conditions	Parkinson's Disease
Enrollment	30 participants
Start Date	2026-06-01
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-18